Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02994251 · ClinicalTrials.gov registry record · Phase 2
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02994251 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 1 participants.
The verdict
NCT02994251, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient follow-up.
Interventions
- DRUG Cisplatin
- DRUG gemcitabine
- DRUG Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2018-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02994251
The ClinicalTrials.gov registry entry for NCT02994251 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02994251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02994251 about?
NCT02994251 is a clinical study titled "A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma". The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC. 25 patients will be enrolled over the course of 2 years, with an additional 1.5 years for patient ...
What is the current status of trial NCT02994251?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-06-21. Estimated completion is 2018-11-06.
What interventions are being tested in trial NCT02994251?
The interventions under investigation include: Cisplatin (DRUG), gemcitabine (DRUG), Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C (DRUG).
Who is sponsoring clinical trial NCT02994251?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.